Carisma Therapeutics, Inc. financial statements, including revenue, expenses, profit, and loss
The total revenue of CARM for the last quarter is 3.40 M USD, and it's 20.80% lower compared to the previous quarter. The net income of Q1 24 is -18.98 M USD.